MedPath

Efficacy of Vonoprazan for sleeping dysorder caused by gastroesophageal reflux disease (GERD) symptoms.

Not Applicable
Conditions
gastroesophageal reflux disease (GERD)
Registration Number
JPRN-UMIN000021521
Lead Sponsor
Machida municipal hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Having oral medicine which may effect gastrointestinal motility. Equivalent to contraindications of the package insert of Vonaprazan. No history of upper gastrointestinal operation.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
An improvement of the sleeping dysorder caused by GERD, in 4, 8, 12 and 16 weeks after start of administration.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath